Cancer diagnosis and treatment often produce psychologic stresses resulting from the actual symptoms of the disease, as well as from perceptions of the disease and its stigma. Depression is seen in many cancer patients. Depression occurs in approximately 25% of palliative care patients. It is widely recognised by clinicians that depression is a difficult symptom to identify amongst patients with advanced illness.
Cancer diagnosis and treatment often produce psy cho logic stresses resulting from the actual symptoms of the disease, as well as from perceptions of the disease and its stigma [1] . Depression is seen in many cancer patients [2] . Depression occurs in approximately 25% of palliative care patients [3] [4] [5] . It is widely recognised by clinicians that depression is a difficult symptom to identify amongst patients with ad vanced illness. This can lead to difficulties in the management of physical symp toms, such as pain, and also cause much dis tress to pa tients and their families [3, 4] . many professionals working in palliative care are concerned that screening for depression may not be appropriate in a population of patients whose illness is changing rapidly [3, 4] . elderly cancer pa tients suffer sig nifi cant psychological distress that should be recognized and effec tively treated [6] . physical symptoms of cancer must be distinguished from the neu rovegetative symp toms of depression.They may be sifted out by asking about pain con trol, fatigue, insomnia, appetite, libido, and psycho motor ac tivity [6] .
The aims of the pilot study of depression were to analyse incidence and relevance of depression among palliative care female patients and to analyse an efect of selected de mo graphics (age), psychosocial (marital status) and health (smoking abuse, number of associated diseases and type of palliative care -palliative chemotherapy, palliative radiation therapy, symp tom atic therapy) aspects on relevance of depression.
Patients and methods
Type of study. The study is prospective and cross-sectional. The dates were obtained during year 2007 -2008 . The The number of all palliative care female patients was 64. The mean age for all 64 subjects was 60,5 years old (aged 29-88 years old). The number of subjects with cancer of lung was 5, with sarcomas 1, with cancer of endometrium 11, with cancer of ovary 7, with cancer of breast 17, with intracranial or extracranial meningeoma 4, with primary brain tumour 6, with cancer of rectum 4, with cancer of ventricle 2, with cancer of gallbladder 2, with melanomas 2, with cancer of pancreas head 2 and cancer of bucall cavity 1. The number of subjects treated with palliative radiation therapy was 29, with palliative chemotherapy 12 and with symptomatic therapy 23. The number of smokers was 11 and non-smokers 35. The number of married patients was 28, widows 10 and divorcee patients 8. The number of patients without associated disease was 3, with 1 asssociated disease 6, with 2 associated diseases 15, with 3 associated diseases 6 and with more than 3 associated diseases 16 . No patient of all 64 patients was treated for depression and have not used antidepressants and anxiolytics. The number of healthy female (control group) was 30 and their mean age was 55 years old (aged 45-63 years old).
Measurement. The Czech version of Zung self-rating depression scale was performed (see Picture 1) [7] . The Zung self-rating depression scale is a short self-administered survey to quantify the depressed status of a patient. There are 20 items on the scale that rate the four common characteristics of depression: the pervasive effect, the physiological equivalents, other disturbances, and psychomotor activities. There are ten positively worded and ten negatively worded questions. Each question is scored on a scale of 1-4 (a little of the time, some of the time, good part of the time, most of the time). The scores range from 25-100. 25-49 normal range. 50-59 mildly depressed. 60-69 moderately depressed. 70 and above severely depressed [7] .
Procedure. The palliative care female patients were tested while hospitalized at the Department of Clinical Oncology and Radiation Therapy of Charles University Hospital in Hradec Kralove, Czech Republic. The filling in the Zung selfrating depression scale was voluntary and anonymous.
Data collection, statistical methods. The dependent variable was Zung self-rating depression scale (SDS). The independent variables were age, marital status, number of associated diseases, smoking abuse, type of palliative care (palliative chemotherapy, palliative radiation therapy, symptomatic therapy). Statistical analysis was performed with analysis of variance (ANOVA). The value p<0,05 was considered significant. Software STATISTICA Base version 7.1 for Windows was used for complete evaluating of dates.
Results

1.
The statistical evaluation presents that mean SDS certifies the presence of signs of mildly depression among palliative care female patients (SDS range was 50-59). The mean SDS in all subjects was 56. The mean SDS in group of healthy females was 38,9 (normal range) (see Graph 1).
2. The incidence of depression is 71,8% (46 of all 64 subjects). The relevance of depression is characterized: severely depressed was proved in 8 of all 46 subjects, the moderately depressed in 21 subjects of all 46 subjects and mildly depressed in 17 of all 46 subjects (see Graph 2).
3. The statistical evaluation not presents statistically significant dependence of SDS on smoking abuse (N=46, p>0,05) 
Discussion
Cancer diagnosis and treatment often produce psychologic stresses resulting from the actual symptoms of the disease, as well as from perceptions of the disease and its stigma. Depression is seen in many cancer patients [3, 4] . Depression occurs in approximately 25% of palliative care patients [3, 4] . It is widely recognised by clinicians that depression is a difficult symptom to identify amongst patients with advanced illness. Depression, the psychiatric syndrome that has received the most attention in individuals with cancer, has been a challenge to study because symptoms occur on a spectrum that ranges from sadness to major affective disorder and because mood change is often difficult to evaluate when a patient is confronted by repeated threats to life, is receiving cancer treatments, is fatigued, or is experiencing pain [8] . However, depression in cancer has been essential to study because comorbid illnesses complicate the treatment of both and may lead to poor adherence to treatment recommendations and less desirable outcomes of both conditions [8] . The severity of medical illness, as manifested by significant pain, declin-ing performance status, or the need for ongoing treatment, is associated with a high risk of comorbid depression. Whether high rates of depression associated with some cancers are caused by the pathophysiologic effect of the tumor (i.e., paraneoplastic syndromes associated with breast, testis, or lung cancers), treatment effects, or other unidentified factors remains to be described. Cancer, exclusive of site, is associated with a rate of depression that is higher than in the general population [8] .
In our pilot study of depression, we found four main outcomes in evaluation incidence and relevance of depression and an effect of selected demographics, psychosocial and health aspects on relevance of depression among palliative care female patients. First, our results had shown that mean SDS certifies the presence of signs of mildly depression among palliative care female patients (SDS range was 50-59). The mean SDS in all subjects was 56. The mean SDS in group of healthy females was 38,9 (normal range). We think that our results correspond to that oncological disease and its therapy is characterized by pain, sleep disturbances, dyspeptic difficulties, immobilization, low self-sufficiency and many others. These difficulties have a negative impact on patient´s physic and mentally condition. Also, these difficulties are associated with psychological and social distress for patient´s families. People with oncological disease in programme of palliative care have significant disability that also affects psychosocial and emotional aspects of their quality of life (QoL). It is an especially important issue in palliative care, as depression can be more common in patients who are at the end of life. Accurate assessment and treatment can have a powerful impact on improving a patient's QoL. Second, our results had shown that incidence of depression in our evaluated group of subjects is 71,8 % (46 of all 64 subjects). The relevance of depression is characterized: severely depressed was proved in 8 of all 46 subjects, moderately depressed in 21 subjects of all 46 subjects and mildly depressed in 17 of all 46 subjects. The results of our prospective study supports Massie´s [8] and Derogatis et al. [9] overview work. Massie [8] and Derogatis et al. [9] present that although many research groups have assessed depression in cancer patients since the 1960s, the reported prevalence (major depression, 0-38 %, depression spectrum syndromes, 0-58 %) varies significantly because of varying conceptualizations of depression, different criteria used to define depression, differences in methodological approaches to the measurement of depression, and different populations studied. We think that incidence of depression symptoms in our patients is high. Also, we think that high incidence of depression symptoms among our patients may be impressed with our minimal applications of antidepressants or anxiolytics (as co-analgetics) in therapy of cancer pain. These findings involve for us, that is a need of routine screening for depression among palliative care patients and its implementation of cost-effective treatment for those who need psychiatric services.
Third, our results not proved statistically significant correlation between SDS and smoking abuse, marital status, age, number of associated diseases and type of palliative care.
Fourth, our results proved that subjects with cancer of lung, with cancer of endometrium, with cancer of gallbladder and with melanomas are moderately depressed (SDS range was 60-69), patients with cancer of ovary, with cancer of breast, with primary brain tumor, with cancer of ventricle, with cancer of pancreas head and with cancer of bucall cavity are mildly depressed (SDS range was 50-59). The incidence of depression in an individual cancers are different. Cancer types highly associated with depression include oropharyngeal (22-57%) [10, 11] , pancreatic (33-50%) [12, 13] , breast (1,5-46%) [14, 15] , and lung (11-44%) [16, 17] . A less high prevalence of depression is reported in patients with other cancers, such as colon (13-25%) [12, 18] , gynecological (12-23%) [19] [20] [21] and lymphoma (8-19%) [22, 23] . Pinder et al. [24] found a 13 % prevalence of depression in advanced breast cancer patients (N=139), increased levels of depression were found in those with lowest socioeconomic status, poorest performance status, and closer proximity to death. Evans et al. [25] studied 83 women with gynecological cancer and found a 23 % prevalence of depression and 24 % prevalence of adjustment disorder with depressed mood. Golden et al. [26] found a 23 % rate of major depression in 83 hospitalized women with cervical, endometrial, and vaginal cancer. Hutton and Williams [27] studied 18 head and neck cancer patients and found that the degree of depression and distress decreased with increasing age. Hammerlind et al. [28] studied 357 head and neck cancer patients and found that patients who reported a higher level of mental distress and frequently scored as a possible or probable case of psychiatric disorder were patients who had lower performance status and more advanced disease. In a study of depression and anxiety in 129 lung can cer patients, before and after diagnosis, Montazeri et al. [17] found that 10 % of patients had severe anxiety symptoms and 12 % had symtoms of depression at first oresentation to their chest physician. Depression, but not anxiety, increased by 10 % at followup. Kramer [29] used Hospital Anxiety and De pression Scale (HADS) as an assessement measure and re ported that 50 % if his sample of 60 patients with in op erable lung cancer were borderline depressed and 37 % were depressed. Joffee et al. [13] found a 33 % prevalence of ma jor depression in patients with pancreas cancer. The reported preva lence fo depression in patients with advanced cancer varies widely. Bukberg et al. [30] found that greater physi cal disability measured by the Karnofsky Rating Scale was asso ciated with depression in their study of 62 patients with can cer. They found a 42 % overall prevalence of depression, but a range of from 23 % (in those with Karnofsky scores greater than 60) to 77 % (in those with Karnofsky scores less than 40). Breibart et al. [31] found a 17 % prevalence of de pression and a 17 % prevalence for a desire for hastened death in a study of 92 terminally ill cancer patients. We subscribe with opinion of LloydWilliams [3, 4] which she emphasizes that the screening and diagnosis of de pression in palliative care patients can help clinicians to help pa tients with depression or demoralization to have a better QoL. Rea sons for failure to diagnose depression are mis con ceptions re garding low mood as being a normal part of a terminal illness and also the patients' reluctance to disclose their thoughts and feelings. Medical and nursing staff working within palliative care may also find difficulty in dis tin guishing between what could be called appropriate sadness and a treatable depressive illness. In an effort to improve the detection of depression, many pro fessionals are using rating scales or tools in order to im prove the diagnosis and treatment [32] . Also, we subscribe with opinion of Miller and Massie [33] which they emphesize that anxiety and de pression are common in patients with cancer and in palliative care settings. These symptoms can be reac tive to the illness or can be related to the direct physiologic effects of the disease or to drug therapies. Effective treatment of these symptoms in cludes both psychopharmacologic and psy cho thera peu tic approaches. The newer antidepressants, anxiolytics, and hypnotics are better tolerated and can be continued safely if necessary, or they can be reduced and discontinued as symp toms improve [33] .
In the future, we would like to analyze incidence and rel evance of depression among palliative care male patients and compare these values with an incidence and relevance of de pression among palliative care female patients. We would like to analyze incidence and relevance of depression among palliative care patients using other depression scale (Hospital Anxiety and Depression Scale, HADS or Beck Depression Inventory, BDI) and its reciprocal comparison. Also, we would like to evaluate an effect of depression on global QoL.
We are also aware of the fact that our study can be limited by a few other factors:
1. The relatively small group of palliative care female pa tients. 2. The study deals only with the effect of selected as pects on relevance of depression. We could add a few other aspects (religion, level of education, effect of individual psy cho logical intervention, effect of antidepressive and anxiolytic therapy i.e.).
In conclusion, depression is common in the general popu lation and in adults and children with cancer and frequently coexists with anxiety and pain [8] . Depression has been chal lenging to study because symptoms occur on a spectrum that ranges from sadness to major affective disorder and because mood change is often difficult to evaluate when a patient is confonted by repeated threaths to life, is receiving cancer treatments, is fatigued, or is experiencing pain. Untreated de pression results in significantly increased morbidity and even mortality [8] .
In summary, our study is the first investigation of screening of depression among palliative care female patients in our country. Our study is one of the few such studie carried out in countries within the former Eastern European bloc. 
